ClinicalTrials.gg
CompletedNCT03630718CBP-HOPEUpdated Jun 25, 2025

Trial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With PBC in Women

An interventional study of Psychoeducational Intervention and Hypnosis intervention in Liver Cirrhosis, Biliary, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Fatigue is a clinical symptom that has been described as the most disturbing by around 50% of patients with PBC. It has an important impact on patients' quality of life and is associated with an increased mortality risk. To treat fatigue in PBC, only medical treatments have been tested with limited efficacy or serious sides' effects. In other diseases, mostly cancer, psychological interventions showed efficacy on fatigue decrease. Most interventions consist in psychoeducation with: education about fatigue, development of self-care or coping techniques, activity management and learning to balance between activities and rest. Hypnosis, which consists in a body work for psycho-therapeutic use (e.g., through imagination), has also shown promising results. Moreover, psychological intervention efficacy seems to be influenced by patients' characteristics, such as personality. Therefore, the first aim of the present single-center randomized controlled phase 2 trial is to assess the efficacy of a psycho educational intervention and a hypnosis intervention on PBC patients' fatigue to demonstrate that both psychoeducational and hypnosis interventions decrease patient fatigue.

02

Conditions studied

  • Liver Cirrhosis, Biliary

Keywords

  • Liver Cirrhosis, Biliary
  • Female
  • Cholangitis
  • Hypnosis
  • Psychological treatment
03

In context

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

This study's enrollment of 55 is close to the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.

Browse Liver Cirrhosis, Biliary studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women from 18 to 75 years old,
  • Diagnosis of primary biliary cholangitis (PBC) according to recognized criteria (EASL 2017),
  • Medically stable under treatment with UDCA initiated for at least 6 months, ie medically stable on the basis of liver biological parameters (no increase of more than 20% in , ALP and transaminases) and absence of disabling pruritus (permanent and EVA> 6/10 or scratching lesions),
  • Presenting a significant level of fatigue (fatigue score on PBC-40>= 33),
  • Understanding the French language,
  • Availability and ability of the patient to access an internet network terminal to answer the online questionnaires of the study,
  • Signed consent form.

Exclusion criteria

Exclusion Criteria:

  • Presence of cirrhosis with a B or C,
  • Presence of disabling pruritus (permanent, or EVA>= 7/10 in the last 3 weeks, or objectivable scratching skin lesions),
  • Patient on liver transplantation waiting list or total > 50 μmol / L (3 mg / dL), or recent complication (\<6 months) of cirrhosis (ascites, hepatic encephalopathy, rupture bleeding) of esophageal varices),
  • Untreated depressive disorder,
  • Any comorbidity not medically controlled (i.e. all dosage changes \<3 months due to a control of the associated pathology deemed insufficient by the referring physician) or life-threatening in the medium term (within 2 years).
  • Psychiatric disorder modifying the relationship to the reality
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • No intervention
    Control Group (CG)

    Patients assigned to no intervention

  • Active comparator
    Psychoeducational Intervention Group (EG-EDU)

    Patients assigned to psychoeducational intervention

    Behavioral: Psychoeducational Intervention

  • Active comparator
    Hypnosis intervention Group (EG-HYP)

    Patients assigned to hypnosis intervention

    Behavioral: Hypnosis intervention

Interventions

  • BehavioralPsychoeducational Intervention

    The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest. The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient.

    Also known as: EG-EDU

  • BehavioralHypnosis intervention

    The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being. Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue.

    Also known as: EG-HYP

06

What researchers measure

Primary outcomes

  1. PBC-40 questionaire

    Time frame: At month 3

Secondary outcomes

  1. Short Form Health Survey (SF36) (1)

    Time frame: At Day 0

  2. Short Form Health Survey (SF36) (2)

    Time frame: At week 5

  3. Short Form Health Survey (SF36) (3)

    Time frame: At month 3

  4. Short Form Health Survey (SF36) (4)

    Time frame: At month 6

  5. Multidimensional fatigue inventory (MFI) (1)

    Time frame: At Day 0

  6. Multidimensional fatigue inventory (MFI) (2)

    Time frame: At week 5

  7. Multidimensional fatigue inventory (MFI) (3)

    Time frame: At month 3

  8. Multidimensional fatigue inventory (MFI) (4)

    Time frame: At month 6

  9. PBC-40 questionaire (1)

    Time frame: At Day 0

  10. PBC-40 questionaire (2)

    Time frame: At week 5

  11. PBC-40 questionaire (3)

    Time frame: At month 6

  12. Pittsburg Sleep Quality Inventory (PSQI) (1)

    Time frame: At Day 0

  13. Pittsburg Sleep Quality Inventory (PSQI) (2)

    Time frame: At week 5

  14. Pittsburg Sleep Quality Inventory (PSQI) (3)

    Time frame: At month 3

  15. Pittsburg Sleep Quality Inventory (PSQI) (4)

    Time frame: At month 6

  16. Epworth Sleeping Scale (ESS) (1)

    Time frame: At Day 0

  17. Epworth Sleeping Scale (ESS) (2)

    Time frame: At week 5

  18. Epworth Sleeping Scale (ESS) (3)

    Time frame: At month 3

  19. Epworth Sleeping Scale (ESS) (4)

    Time frame: At month 6

  20. Hospital Anxiety and Depression Scale (HADS) (1)

    Time frame: At Day 0

  21. Hospital Anxiety and Depression Scale (HADS) (2)

    Time frame: At week 5

  22. Hospital Anxiety and Depression Scale (HADS) (3)

    Time frame: At month 3

  23. Hospital Anxiety and Depression Scale (HADS) (4)

    Time frame: At month 6

07

Study locations

1 site
  • Service hépatologie Hôpital Saint-Antoine
    Paris, 75012, France
08

References and documents

Publications

  • Untas A, Goffette C, Flahault C, Vioulac C, Chazouilleres O, Soret PA, Ben Belkacem K, Gaouar F, Bernard N, Rousseau A, Corpechot C. PBC-HOPE: A Randomized Controlled Trial of Hypnosis and Psychoeducation in Women With Primary Biliary Cholangitis and Fatigue. Am J Gastroenterol. 2025 Jul 14. doi: 10.14309/ajg.0000000000003639. Online ahead of print. PubMed 40658125 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in May 2023, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2018
First posted
Aug 15, 2018
StartActual
May 27, 2019
Primary completionActual
May 17, 2023
CompletionActual
May 22, 2023
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03630718
Collaborators
University of Paris 5 - Rene Descartes
Responsible party
Sponsor
First posted
Aug 15, 2018
Start date
May 27, 2019
Primary completion
May 17, 2023
Completion
May 22, 2023
Last update
Jun 25, 2025

Study contacts

Christophe CORPECHOT, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion